Cargando…

Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition

Medulloblastoma (MB) is the most common malignant brain tumour in children. High-risk MB patients harbouring MYC amplification or overexpression exhibit a very poor prognosis. Aberrant activation of MYC markedly reprograms cell metabolism to sustain tumorigenesis, yet how metabolism is dysregulated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Graziani, Vittoria, Garcia, Aida Rodriguez, Alcolado, Lourdes Sainero, Le Guennec, Adrien, Henriksson, Marie Arsenian, Conte, Maria R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870962/ https://www.ncbi.nlm.nih.gov/pubmed/36690651 http://dx.doi.org/10.1038/s41598-023-27375-z

Ejemplares similares

Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
por: Bolin, Sara, et al.
Publicado: (2018)

Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma
por: Bandopadhayay, Pratiti, et al.
Publicado: (2019)

Targeting mitochondrial metabolism for precision medicine in cancer
por: Sainero-Alcolado, Lourdes, et al.
Publicado: (2022)

Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains
por: Lambert, Jean-Philippe, et al.
Publicado: (2019)

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
por: Henssen, Anton, et al.
Publicado: (2013)

MBRS-02. BET BROMODOMAIN PROTEIN-KINASE INHIBITOR COMBINATIONS FOR THE TREATMENT OF MEDULLOBLASTOMA
por: Ayad, Nagi, et al.
Publicado: (2020)

Expression and activation of nuclear hormone receptors result in neuronal differentiation and favorable prognosis in neuroblastoma
por: Sainero-Alcolado, Lourdes, et al.
Publicado: (2022)

Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors
por: Tolani, Bhairavi, et al.
Publicado: (2013)

Development of hedgehog pathway inhibitors by epigenetically targeting GLI through BET bromodomain for the treatment of medulloblastoma
por: Liu, Xiaohua, et al.
Publicado: (2021)

Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
por: Kandela, Irawati, et al.
Publicado: (2015)

Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
por: Aird, Fraser, et al.
Publicado: (2017)

Selective inhibition of BET bromodomains
por: Filippakopoulos, Panagis, et al.
Publicado: (2010)

A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma
por: Kling, Matthew J., et al.
Publicado: (2022)

Correction: Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
por: Aird, Fraser, et al.
Publicado: (2018)

P1212: RATIONALLY DESIGNED CHIMERIC PI3K-BET BROMODOMAIN INHIBITORS ELICIT CURATIVE RESPONSES IN MYC-DRIVEN LYMPHOMA
por: Oh, Danielle H., et al.
Publicado: (2023)

Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo
por: Jonchere, Barbara, et al.
Publicado: (2023)

MYCN-enhanced Oxidative and Glycolytic Metabolism Reveals Vulnerabilities for Targeting Neuroblastoma
por: Oliynyk, Ganna, et al.
Publicado: (2019)

Targeting BET bromodomain proteins in solid tumors
por: Sahai, Vaibhav, et al.
Publicado: (2016)

Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer
por: Coleman, Daniel J., et al.
Publicado: (2019)

Mouse medulloblastoma driven by CRISPR activation of cellular Myc
por: Vo, BaoHan T., et al.
Publicado: (2018)

Targeting protein folding in N‐Myc‐driven medulloblastoma
por: Valinciute, Gintvile, et al.
Publicado: (2023)

BET bromodomain proteins are required for glioblastoma cell proliferation
por: Pastori, Chiara, et al.
Publicado: (2014)

When are the BET factors the most sensitive to bromodomain inhibitors?
por: Khochbin, Saadi
Publicado: (2013)

Bromodomain Blockade for Intimal Hyperplasia — A Good BET?
por: Ostriker, Allison C., et al.
Publicado: (2015)

BET bromodomain inhibitor (JQ1) and tumor angiogenesis
por: Bid, Hemant Kumar, et al.
Publicado: (2016)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Veppil Muralidharan, Somsundar, et al.
Publicado: (2017)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Muralidharan, Somsundar Veppil, et al.
Publicado: (2017)

Chemical probes and inhibitors of bromodomains outside the BET family
por: Moustakim, Moses, et al.
Publicado: (2016)

Selective BET bromodomain inhibition as an antifungal therapeutic strategy
por: Mietton, Flore, et al.
Publicado: (2017)

Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
por: Mao, Wendy, et al.
Publicado: (2019)

The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins
por: Taniguchi, Yasushi
Publicado: (2016)

The Multiple Faces of MNT and Its Role as a MYC Modulator
por: Liaño-Pons, Judit, et al.
Publicado: (2021)

GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1
por: Kumar, Krishan, et al.
Publicado: (2015)

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
por: Wyce, Anastasia, et al.
Publicado: (2013)

The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling
por: Díaz, Tania, et al.
Publicado: (2017)

BET bromodomain inhibition suppresses T(H)17-mediated pathology
por: Mele, Deanna A., et al.
Publicado: (2013)

Dietary Compound Resveratrol Is a Pan-BET Bromodomain Inhibitor
por: Dutra, Luiz Antonio, et al.
Publicado: (2017)

BET bromodomain proteins regulate enhancer function during adipogenesis
por: Brown, Jonathan D., et al.
Publicado: (2018)

BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
por: To, Kenneth K. W., et al.
Publicado: (2023)

BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc
por: Li, Ning, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lamkna5l0cv3u1j5lsom8ui4o7